Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019163 (
hepatitis B
)
38,309
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Secreted frizzled-related proteins (SFRPs) are antagonists of the Wnt signaling pathway whose epigenetic downregulation have been shown to be involved in hepatocarcinogenesis. However, dysregulation of SFRPs induced by
hepatitis B
virus (HBV) X protein (HBx) has never been studied in HBV-related hepatocellular carcinoma (HBV-HCC). In this study, we sought to determine the clinical significance and underlying mechanism of HBx-induced SFRPs dysregulation in hepatoma cells and HBV-HCC patients. Our results showed that SFRP1 and
SFRP5
expression were dramatically decreased by HBx in hepatoma cells. The repressed expression in hepatoma cells was partially rescued by a DNA methylation inhibitor and synergistically increased by a combination treatment with a histone deacetyltransferases inhibitor. In addition, we identified that SFRP1 and
SFRP5
promoters were hypermethylated in both HBx-expressing hepatoma cells and HBV-HCC tissues. Downregulation of SFRP1 and
SFRP5
in HBV-HCC tissues was significantly correlated with overexpression of DNA methyltransferase 1 (DNMT1) and poor tumor differentiation. HBx facilitated the binding of DNMT1 and DNMT3A to SFRP1 and
SFRP5
promoters, and resulted in epigenetic silencing of SFRP1 and
SFRP5
. Moreover, overexpression of SFRP1,
SFRP5
or RNA interference mediated silencing of DNMT1 inactivated the Wnt signaling pathway and decreased the expression levels of Wnt target genes c-Myc and CyclinD1, thus impeding HCC growth in vitro and in vivo, and regressing HBx-induced epithelial-mesenchymal transition (EMT). Our findings strongly suggest that epigenetic silencing of SFRP1 and
SFRP5
by HBx allows constitutive activation of Wnt signaling pathway and hence contributes to hepatocarcinogenesis.
...
PMID:Epigenetic silencing of SFRP1 and SFRP5 by hepatitis B virus X protein enhances hepatoma cell tumorigenicity through Wnt signaling pathway. 2437 50
The aim of this study was to investigate the characteristics of serum
secreted frizzled-related protein 5
(
SFRP5
), an inhibitor of Wnt signaling, in
hepatitis B
virus (HBV)-associated infections and hepatocellular carcinoma (HCC) patients. Serum
SFRP5
levels were detected in 147 patients with HBV-associated chronic infection or HCC. Compared with the non-HBV-infected and non-HCC group, the HBV-associated chronic infection and HCC groups exhibited decreased serum
SFRP5
levels. A significant inverse correlation between serum
SFRP5
levels and HBV DNA levels was identified in the HBV-associated chronic infection and HCC groups. Furthermore,
SFRP5
levels differentially decreased in patients with HBV-associated diseases, in a manner which was dependent on liver disease status. Compared with patients exhibiting HBV-associated chronic infection, patients with HCC were found to exhibit lower serum
SFRP5
levels. The results of the present study indicated that patients with HBV-associated liver infection and HCC exhibited significantly deceased serum
SFRP5
levels, which were found to negatively correlate with HBV DNA levels. Serum
SFRP5
levels may present a biomarker for the severity of HBV-associated liver infection, and the risk of HCC initiation and progression.
...
PMID:Serum secreted frizzled-related protein 5 levels differentially decrease in patients with hepatitis B virus-associated chronic infection and hepatocellular carcinoma. 2512 Jul 20